Dr. Martens Past Earnings Performance
Past criteria checks 2/6
Dr. Martens has been growing earnings at an average annual rate of 2.1%, while the Luxury industry saw earnings growing at 16.5% annually. Revenues have been declining at an average rate of 0.8% per year. Dr. Martens's return on equity is 8.8%, and it has net margins of 3.6%.
Key information
2.1%
Earnings growth rate
2.2%
EPS growth rate
Luxury Industry Growth | 27.6% |
Revenue growth rate | -0.8% |
Return on equity | 8.8% |
Net Margin | 3.6% |
Next Earnings Update | 05 Jun 2025 |
Recent past performance updates
Recent updates
Earnings Tell The Story For Dr. Martens plc (LON:DOCS) As Its Stock Soars 27%
Dec 06Dr. Martens plc (LON:DOCS) Half-Yearly Results: Here's What Analysts Are Forecasting For This Year
Dec 01Benign Growth For Dr. Martens plc (LON:DOCS) Underpins Stock's 30% Plummet
Sep 21Is There An Opportunity With Dr. Martens plc's (LON:DOCS) 45% Undervaluation?
Aug 20Dr. Martens (LON:DOCS) Has Some Way To Go To Become A Multi-Bagger
Jul 20There May Be Some Bright Spots In Dr. Martens' (LON:DOCS) Earnings
Jun 19Dr. Martens plc's (LON:DOCS) Price Is Right But Growth Is Lacking After Shares Rocket 27%
May 21The Trend Of High Returns At Dr. Martens (LON:DOCS) Has Us Very Interested
Mar 27Dr. Martens (LON:DOCS) Has A Somewhat Strained Balance Sheet
Mar 06Dr. Martens plc's (LON:DOCS) Intrinsic Value Is Potentially 57% Above Its Share Price
Feb 08Dr. Martens plc's (LON:DOCS) Business And Shares Still Trailing The Market
Jan 21Dr. Martens' (LON:DOCS) Dividend Will Be £0.0156
Jan 03Dr. Martens (LON:DOCS) Will Pay A Dividend Of £0.0156
Dec 13Dr. Martens (LON:DOCS) Is Very Good At Capital Allocation
Oct 12Calculating The Intrinsic Value Of Dr. Martens plc (LON:DOCS)
Sep 13Returns on Capital Paint A Bright Future For Dr. Martens (LON:DOCS)
Jul 12A Look At The Intrinsic Value Of Dr. Martens plc (LON:DOCS)
Jun 02Dr. Martens (LON:DOCS) Is Investing Its Capital With Increasing Efficiency
Feb 25Is There An Opportunity With Dr. Martens plc's (LON:DOCS) 34% Undervaluation?
Dec 17The Trend Of High Returns At Dr. Martens (LON:DOCS) Has Us Very Interested
Oct 02Dr. Martens (LON:DOCS) Knows How To Allocate Capital Effectively
Jul 04Why Investors Shouldn't Be Surprised By Dr. Martens plc's (LON:DOCS) 26% Share Price Surge
Jun 16Revenue & Expenses Breakdown
How Dr. Martens makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 806 | 29 | 386 | 0 |
30 Jun 24 | 842 | 49 | 382 | 0 |
31 Mar 24 | 877 | 69 | 378 | 0 |
31 Dec 23 | 927 | 86 | 386 | 0 |
30 Sep 23 | 978 | 103 | 395 | 0 |
30 Jun 23 | 989 | 116 | 384 | 0 |
31 Mar 23 | 1,000 | 129 | 373 | 0 |
31 Dec 22 | 979 | 153 | 372 | 0 |
30 Sep 22 | 957 | 177 | 371 | 0 |
30 Jun 22 | 933 | 179 | 343 | 0 |
31 Mar 22 | 908 | 181 | 316 | 0 |
31 Dec 21 | 867 | 118 | 310 | 0 |
30 Sep 21 | 825 | 54 | 304 | 0 |
30 Jun 21 | 799 | 44 | 276 | 0 |
31 Mar 21 | 773 | 35 | 248 | 0 |
31 Dec 20 | 747 | 61 | 219 | 0 |
30 Sep 20 | 722 | 87 | 191 | 0 |
30 Jun 20 | 697 | 81 | 204 | 0 |
31 Mar 20 | 672 | 75 | 217 | 0 |
31 Mar 19 | 454 | 17 | 124 | 0 |
31 Mar 18 | 349 | -6 | 94 | 0 |
31 Mar 17 | 291 | -11 | 75 | 0 |
31 Mar 16 | 232 | -12 | 56 | 0 |
31 Mar 15 | 235 | 0 | 50 | 0 |
31 Mar 14 | 164 | -32 | 24 | 0 |
Quality Earnings: DOCS has high quality earnings.
Growing Profit Margin: DOCS's current net profit margins (3.6%) are lower than last year (10.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DOCS's earnings have grown by 2.1% per year over the past 5 years.
Accelerating Growth: DOCS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DOCS had negative earnings growth (-71.5%) over the past year, making it difficult to compare to the Luxury industry average (2.4%).
Return on Equity
High ROE: DOCS's Return on Equity (8.8%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/18 20:49 |
End of Day Share Price | 2024/12/18 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dr. Martens plc is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Richard Taylor | Barclays |
David Roux | BofA Global Research |
Louise Singlehurst | Goldman Sachs |